{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Checkpoint+Blockade%2C+Immune&page=2", "query": { "intervention": "Checkpoint Blockade, Immune", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Checkpoint+Blockade%2C+Immune&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T10:07:46.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage IV" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-02-20", "completion_date": "2020-07-01", "has_results": false, "last_update_posted_date": "2023-05-15", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275597" }, { "nct_id": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Gastric Adenocarcinoma", "Esophageal Adenocarcinoma", "Castration Resistant Prostate Adenocarcinoma", "Soft Tissue Sarcoma", "Ovarian Adenocarcinoma", "Advanced Well-differentiated Neuroendocrine Tumors", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "LAG525", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2018-01-24", "completion_date": "2020-09-17", "has_results": true, "last_update_posted_date": "2022-05-27", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 20, "location_summary": "San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03365791" }, { "nct_id": "NCT03025035", "title": "Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yuan Yuan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-09-10", "completion_date": "2025-11-21", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03025035" }, { "nct_id": "NCT05013450", "title": "Dupilumab_Metastatic NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "PD-1/PD-L1 blockade", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Marron", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2021-09-10", "completion_date": "2030-09-18", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013450" }, { "nct_id": "NCT04042506", "title": "SBRT as a Vaccination for Metastatic Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-11-26", "completion_date": "2021-01-26", "has_results": false, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04042506" }, { "nct_id": "NCT04375228", "title": "Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune-related Adverse Events", "Advanced Solid Tumor" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-25", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375228" }, { "nct_id": "NCT03007407", "title": "Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2017-07-31", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2022-12-05", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 18, "location_summary": "Duarte, California • New Haven, Connecticut • North Haven, Connecticut + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03007407" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 18, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT07281924", "title": "Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Liver Metastases" ], "interventions": [ { "name": "Nivolumab and Relatlimab", "type": "DRUG" }, { "name": "Melphalan", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-21T10:07:46.533Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281924" } ] }